MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 10,907 shares of the company’s stock, valued at approximately $190,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. LMR Partners LLP purchased a new stake in shares of Bicara Therapeutics during the 4th quarter valued at $264,000. Deutsche Bank AG purchased a new stake in shares of Bicara Therapeutics during the 4th quarter valued at $1,959,000. DAFNA Capital Management LLC purchased a new stake in shares of Bicara Therapeutics during the 4th quarter valued at $1,838,000. Deep Track Capital LP raised its position in shares of Bicara Therapeutics by 151.0% during the 4th quarter. Deep Track Capital LP now owns 2,000,000 shares of the company’s stock valued at $34,840,000 after buying an additional 1,203,148 shares in the last quarter. Finally, Braidwell LP raised its position in shares of Bicara Therapeutics by 20.7% during the 4th quarter. Braidwell LP now owns 2,000,659 shares of the company’s stock valued at $34,851,000 after buying an additional 343,059 shares in the last quarter.

Analysts Set New Price Targets

A number of brokerages recently commented on BCAX. Stifel Nicolaus set a $48.00 target price on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Wall Street Zen cut shares of Bicara Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. HC Wainwright decreased their target price on shares of Bicara Therapeutics from $44.00 to $41.00 and set a “buy” rating on the stock in a research report on Friday, May 16th. Wedbush reiterated an “outperform” rating and issued a $30.00 target price on shares of Bicara Therapeutics in a research report on Friday, May 23rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.01 target price on shares of Bicara Therapeutics in a research report on Thursday, March 13th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $31.86.

Bicara Therapeutics Price Performance

Shares of Bicara Therapeutics stock opened at $9.28 on Monday. Bicara Therapeutics Inc. has a 12-month low of $7.80 and a 12-month high of $28.09. The company’s fifty day simple moving average is $12.54 and its two-hundred day simple moving average is $14.36.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.28). As a group, equities analysts forecast that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.